MANKIND Mankind Pharma Q4 FY25 results (Jan–Mar 2025) and concall
Mankind Pharma delivered strong Q4 and FY25 results, with robust revenue growth driven by chronic segment outperformance and successful BSV integration. Adjusted EBITDA margins exceeded guidance for FY25, supported by gross margin expansion. While PAT saw a decline in Q4 due to integration-related costs and higher depreciation, the company remains optimistic about future growth, particularly in chronic and specialty segments, and aims for further debt reduction and margin improvement.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 |
|---|---|---|
| Revenue | 3,199 | 3,079 |
| EBITDA | 816 | 683 |
| Net profit | 385 | 425 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
